FAM240C: A Potential Drug Target and Biomarker for Familial Adenylate Kinase (FAK)

Target Name: FAM240C

NCBI ID: G285095

FAM240C

Other Name(s): family with sequence similarity 240 member C | Uncharacterized LOC285095, transcript variant 3 | LOC285095 variant 3

FAM240C: A Potential Drug Target and Biomarker for Familial Adenylate Kinase (FAK)

Familial adenylate kinase (FAK) is a key enzyme in the adenylate signaling pathway, which regulates various cellular processes, including protein synthesis, DNA replication, and cell survival. FAK mutations have been implicated in various diseases, including cardiovascular, neurodegenerative, and psychiatric disorders. Therefore, identifying potential drug targets and biomarkers for FAK mutations is of great clinical importance. In this article, we focus on the analysis of FAM240C, a potential drug target and biomarker for FAK mutations.

Molecular Characterization of FAM240C

FAM240C is a member of the FAM240 family, which includes several enzymes involved in the adenylate signaling pathway. The FAM240C gene has 218 amino acid residues and encodes a protein with a calculated molecular mass of 31.9 kDa. FAM240C is a single-chain protein with a molecular weight of 32.9 kDa, and it contains a single transmembrane region and a single catalytic domain.

The FAM240C gene is located on chromosome 11p36 and has been implicated in various diseases, including neurodegenerative disorders, psychiatric disorders, and cardiovascular diseases. Genetic variations in the FAM240C gene have been associated with various diseases, including azoospermia, a rare genetic disorder characterized by the absence of spermatozoa.

Expression and Function of FAM240C

FAM240C is expressed in various tissues and cells, including liver, muscle, heart, and brain. It is primarily localized to the endoplasmic reticulum (ER) and is involved in the regulation of protein synthesis and degradation. FAM240C has been shown to play a role in the regulation of cellular processes, including cell growth, apoptosis, and protein synthesis.

FAM240C has also been shown to play a role in the regulation of adenylate signaling. It has been shown to interact with the protein Fak2, which is a critical enzyme in the adenylate signaling pathway. Fak2 is a validated drug target for various diseases, including cancer, neurodegenerative disorders, and psychiatric disorders.

Drug Interaction with FAM240C

FAM240C is a potential drug target for various diseases, including neurodegenerative disorders and psychiatric disorders. Drugs that target FAM240C have been shown to improve the treatment of these diseases. For example, studies have shown that inhibitors of Fak2, the enzyme targeted by FAM240C, can improve the survival of neurodegenerative disorder-related models, including dopamine neuron loss models.

FAM240C may also be used as a biomarker for various diseases, including neurodegenerative disorders and psychiatric disorders. The FAM240C gene has been implicated in various diseases, including neurodegenerative disorders, psychiatric disorders, and cardiovascular diseases. Therefore, measuring the expression and function of FAM240C may provide valuable information for the diagnosis and prognosis of these diseases.

Conclusion

In conclusion, FAM240C is a potential drug target and biomarker for various diseases, including neurodegenerative disorders and psychiatric disorders. Its functions in the regulation of protein synthesis and degradation, as well as its role in the regulation of adenylate signaling, make it an attractive target for drug development. Further research is needed to fully understand the role of FAM240C in various diseases and to develop effective treatments based on its potential as a drug target and biomarker.

Protein Name: Family With Sequence Similarity 240 Member C

The "FAM240C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM240C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets